Shanghai Pharmaceuticals Holding Co Ltd
F:S1R
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
F:S1R
|
CN |
|
G
|
Globrands Group Ltd
OTC:GLBGF
|
IL |
|
P
|
Pan American Silver Corp
LSE:0R07
|
CA |
|
Clean Seed Capital Group Ltd
XTSX:CSX
|
CA |
|
argenx SE
XBRU:ARGX
|
NL |
|
Sekisui House Ltd
OTC:SKHSF
|
JP |
|
Catalyst Metals Ltd
OTC:CTYMF
|
AU |
|
A
|
Allkem Ltd
F:3O10
|
AU |
|
Orient Overseas (International) Ltd
F:ORI
|
HK |
Wall St Price Targets
S1R Price Targets Summary
Shanghai Pharmaceuticals Holding Co Ltd
According to Wall Street analysts, the average 1-year price target for S1R is 1.63 EUR with a low forecast of 0.98 EUR and a high forecast of 2.12 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S1R's stock price target?
Price Target
1.63
EUR
According to Wall Street analysts, the average 1-year price target for S1R is 1.63 EUR with a low forecast of 0.98 EUR and a high forecast of 2.12 EUR.
What is the Revenue forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 7%.
What is the Operating Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
8%
Over the last 14 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 3 years is 8%.
What is the Net Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 3 years is 5%.
